Viatris Earnings Preview: What to Expect [Yahoo! Finance]
Viatris Inc. (VTRS)
Company Research
Source: Yahoo! Finance
Headquartered in Canonsburg, Pennsylvania, it develops, manufactures and distributes a broad portfolio of generic, branded, complex generic and biosimilar medicines across more than 165 countries and territories, supplying high-quality medicines to roughly 1 billion patients globally each year. The global healthcare giant is expected to announce its fiscal 2025 fourth-quarter earnings soon. Ahead of the event, analysts expect VTRS to report a profit of $0.53 per share on a diluted basis, down 1.9% from $0.54 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion. CEO Sanjay Mehrotra Says Demand for Memory Will Keep Lifting Micron Stock for Years to Come The New Wegovy Pill Is Already Popular. Does That Make Novo Nordisk Stock a Buy for Q1? Dear IBM Stock Fans, Mark Your Calendars for January 28 Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you
Show less
Read more
Impact Snapshot
Event Time:
VTRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTRS alerts
High impacting Viatris Inc. news events
Weekly update
A roundup of the hottest topics
VTRS
News
- Davis Opportunity Fund Annual Review 2026 [Seeking Alpha]Seeking Alpha
- Viatris (VTRS) Valuation Check After First International Inpefa Heart Failure Launch [Yahoo! Finance]Yahoo! Finance
- Is Viatris (VTRS) Pricing Reflect Its Recent Multi-Year Share Price Recovery [Yahoo! Finance]Yahoo! Finance
- 3 Reasons to Sell VTRS and 1 Stock to Buy Instead [Yahoo! Finance]Yahoo! Finance
- Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure [Yahoo! Finance]Yahoo! Finance
VTRS
Earnings
- 11/6/25 - Beat
VTRS
Sec Filings
- 1/2/26 - Form 4
- 12/8/25 - Form 8-K
- 12/5/25 - Form 8-K
- VTRS's page on the SEC website